Tyme Technologies Inc. (TYME)

[mcsharkey]

Shot myself in the foot with yesterday's entry about possibility of buying back our rights from EAGLE Pharma Hanuman! Went off on the forward looking statement on new collaborations. My statement was a delusional hope.

From the INCOME section of yesterday's 10Q:Disappointing Excerpt from yesterday's 10Q, REVENUES section:
Revenues: During the three months ended June 30, 2020 and 2019, the Company did not realize any revenues from operations. We do not anticipate any revenues until such time as one of our products has been approved for commercialization by appropriate regulatory authorities, or we enter into certain types of collaboration or licensing arrangements, none of which is anticipated to occur in the near future.

(excerpt) from January 2020 Press Release........."Under the terms of the co-promotion agreement, Eagle Pharmaceuticals will undertake 25% of the promotional sales effort for SM-88 in the U.S. oncology market and receive 15% of the net U.S. revenues of SM-88, and TYME will be responsible for the remaining promotional effort. TYME will also be responsible for clinical development, regulatory approval, commercial strategy, marketing, reimbursement and manufacturing of SM-88. TYME retains the remaining 85% of net U.S. revenues and reserves the right to repurchase Eagle’s co-promotion right for $200 million......"

LINK

Ahhh. S3 Shelf Offering yesterday raising capital only.

My apologies.